Shuttle Pharmaceuticals Holdings Inc. (SHPH) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

SHPH scores 41 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow."

• Fundamental Cash Engine (7 / 20): Per the RQD rating, ROIC is -35% and FCF yield is 0%. FY 2025 free cash flow was -$9.5M against revenue of —, so the business is consuming cash rather than generating it. For a prospective investor, there is no cash-flow valuation floor in the source data.
• Whale / 13F Flow (9 / 20): The RQD rating assigns 9 / 20 to institutional accumulation and options positioning. The holders section contains no 13F data, so the basis for this score cannot be verified from the source data provided.
• Insider Conviction (5 / 20): Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow scores 5 / 20.
• Macro Regime Fit (10 / 20): Per the RQD rating, beta is 1.0 with sector sensitivity scoring 10 / 20. A beta of 1.0 means the stock is expected to move in line with the broad market, offering no defensive cushion.
• Forensic Balance Sheet (10 / 20): Per the RQD rating, Altman Z is 2.5, Piotroski F is 1/9, and Debt/Equity is 0.5. The weak Piotroski reading indicates poor financial-health signals, while the Altman figure sits in a range that does not by itself signal distress.

Investor implications: The main upside driver cited in the source data is the liquidity signal in the Butterfly graph (see below), which is a macro-positioning factor rather than an operating one. The valuation tradeoff is stark: with negative ROIC, zero FCF yield, and a market capitalization of $24.9M, the equity rests on future outcomes that the provided financials do not evidence. The 52-week range of $2.58 - $44.4 shows extreme price dispersion, which signals high volatility for a prospective holder.

Shuttle Pharmaceuticals Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile does not describe its products, customers, or revenue model. Reported revenue is — for each of FY 2025, FY 2024, and FY 2023. —: product pipeline, end customers, and monetization mechanism.

The company reported operating losses in every period shown, with operating loss widening from -$5.9M (FY 2023) to -$11.9M (FY 2025). Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9. Cash declined from $1.9M to $0.

• 🐂 Primary Bull Case: The Butterfly graph flags a BULLISH liquidity tailwind with a Macro Tailwind Score of 90/100, though its correlation is weak (r = -0.16). With Fundamental Cash Engine at 7/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 9/20, sustained execution supports upside toward the top of the $2.58 – $44.40 52-week range.
• 🐻 Primary Bear Case: With zero reported revenue, ROIC of -35%, FCF of -$9.5M in FY 2025, and an auditor exit pending, the balance sheet and cash flow are weak. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

Per the Butterfly graph, supply_chain is NONE and butterfly_links is empty, so no upstream or downstream dependencies are mapped. —: supplier, customer, and partner relationships. The only sector context is Health Care / Biotechnology: Pharmaceutical Preparations. Investors should watch the auditor transition as a 2nd-order governance bottleneck, since an unfilled audit role could delay reporting. The liquidity beta is a macro sensitivity rather than an operating linkage, and its weak correlation limits its predictive use.

• Key Question #1: Who is the current auditor, and has a successor been engaged ahead of Q3 reporting?
• Key Question #2: What is the total debt balance, since debt is listed as N/A in every reported period?
• Key Question #3: What is the basis for the 13F and insider scores in the RQD rating, given that the holders section is empty?